Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Platelet Factor 4 Antibody Clonal Heterogeneity and MGUS Status in HIT.

medRxiv : the preprint server for health sciences·2026
Same author

Gephyrin Neurological Autoimmunity.

Annals of neurology·2026
Same author

Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.

Brain : a journal of neurology·2026
Same author

Reference Material Choice Affects LC-MS/MS Infliximab Quantitation.

The journal of applied laboratory medicine·2026
Same author

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD.

bioRxiv : the preprint server for biology·2026
Same author

Long-Term Outcomes in Stiff Person Spectrum Disorder.

European journal of neurology·2026

Related Experiment Video

Updated: Oct 10, 2025

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.2K

CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis.

Ruba S Saadeh1, Sandra C Bryant2, Andrew McKeon1

  • 1Departments of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Neurology, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|December 11, 2021
PubMed
Summary
This summary is machine-generated.

A new cerebrospinal fluid (CSF) kappa light chain (KCSF) test offers a reliable alternative to oligoclonal band (OCB) testing for multiple sclerosis (MS) diagnosis. This quantitative KCSF test provides comparable accuracy, reduces costs, and minimizes errors in MS diagnostics.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.2K

Related Experiment Videos

Last Updated: Oct 10, 2025

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.2K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.2K

Area of Science:

  • Neurology
  • Clinical Chemistry
  • Immunology

Background:

  • Multiple sclerosis (MS) diagnosis relies on detecting specific biomarkers in cerebrospinal fluid (CSF).
  • Oligoclonal band (OCB) detection in CSF is a standard method, but it can be subjective and time-consuming.
  • A quantitative CSF kappa light chain (KCSF) assay may offer a more standardized and efficient alternative.

Purpose of the Study:

  • To establish and validate a CSF kappa light chain (KCSF) level comparable to CSF-specific oligoclonal band (OCB) detection for supporting multiple sclerosis (MS) diagnosis.
  • To evaluate the diagnostic performance of KCSF testing against OCB testing in both retrospective and prospective cohorts.

Main Methods:

  • Analysis of 1,359 paired CSF/serum samples (702 retrospective, 657 prospective) from patients undergoing OCB testing.
  • Neurological chart review by blinded experts to confirm diagnoses.
  • Statistical evaluation of sensitivity and specificity to determine a diagnostic cutoff for KCSF (0.1 mg/dL) and validate its performance against OCB detection.

Main Results:

  • A KCSF cutoff value of 0.1 mg/dL was established and validated.
  • In the prospective cohort, KCSF and OCB testing showed comparable sensitivities (78.6% vs 78.6%) and specificities (87.1% vs 89.4%) for MS diagnosis.
  • Receiver operating characteristic curve analysis indicated strong diagnostic performance for both KCSF and OCB.

Conclusions:

  • A KCSF value of 0.1 mg/dL serves as a valid, quantitative alternative to OCB testing for supporting MS diagnosis.
  • KCSF testing offers advantages including standardization, reduced human error, lower costs, and faster turnaround times.
  • Class I evidence supports the use of KCSF testing in place of OCB testing for MS diagnosis.